The Technological Renaissance in Diabetes Management

Figure 1: Diabetes Managment

Introduction: The Growing Crisis

Diabetes is one of the most common chronic diseases on the planet. Diabetes mellitus has reached the level of a global health emergency. As of 2024–2025, approximately 589 million adults worldwide are living with the condition, and this number continues to rise. For decades, managing diabetes has meant a demanding daily routine pricking fingers to check blood sugar, calculating insulin doses, counting carbohydrates, and living with the constant risk that levels could swing dangerously high or low. While these tools have kept millions alive, they share a common limitation: they manage symptoms without addressing the root cause. That is starting to change. A wave of scientific breakthroughs, new medications, and advanced technologies is transforming how diabetes is treated, monitored, and even potentially cured. In the United States, the impact is particularly acute. The CDC reports that 40.1 million Americans have diabetes, with over 1 in 4 adults unaware they have the disease. This crisis has necessitated a shift from traditional, reactive care to a proactive, technology-driven ecosystem.

Therapy for Cure

The most significant shift in daily management has been the universal adoption of Continuous Glucose Monitoring (CGM). Modern devices like the Dexcom G7, Abbott’s FreeStyle Libre 3 Plus, and the 365-day implantable Eversense 365 have achieved high accuracy, typically measured by a Mean Absolute Relative Difference (MARD) below 10%.

In 2025 and 2026, the market expanded significantly with the introduction of Over-the-Counter (OTC) sensors for non-insulin-using adults, such as Dexcom Stelo and Abbott Lingo. Additionally, needle-free options like the Biolinq Shine—an intradermal sensor that sits just below the skin’s surface—received FDA clearance in late 2025, offering a more comfortable alternative for those with needle phobias.

Vertex Pharmaceuticals is leading the way with VX-880, a therapy that uses laboratory-grown insulin-producing cells derived from stem cells. These cells are infused into the patient's liver, where they engraft and begin producing insulin just like healthy beta cells would.

On March 26, 2026, the FDA approved Awiqli (insulin icodec) by Novo Nordisk — the first insulin that needs to be injected only once per week. This single change reduces basal insulin injections from 365 per year to just 52, a meaningful improvement in quality of life for millions of people with type 2 diabetes. Clinical trials showed that Awiqli worked as well as the best daily insulins without increasing the risk of low blood sugar.

The popular class of GLP-1 receptor agonists — which includes medications like Ozempic, Wegovy, and Mounjaro — continues to expand in both formulation and scope. Eli Lilly is developing orforglipron, a once-daily pill that delivers comparable benefits to injectable GLP-1 drugs, reducing a key blood sugar measure by up to 2.1 percentage points in trials.

Technological Advancements

Existing continuous glucose monitors have also taken major steps. The Eversense 365 system now lasts a full year under the skin, and both Dexcom and Abbott have shown real-world improvements in blood sugar control for people with type 2 diabetes who are not even on insulin. For those requiring insulin, Automated Insulin Delivery (AID) systems often called "hybrid closed loop" systems have become the preferred delivery method. These systems (such as Omnipod 5, Tandem X2, and Medtronic 780G) use algorithms to automatically adjust insulin based on real-time CGM data. These systems combine a glucose sensor, insulin pump, and AI algorithm that automatically adjusts insulin delivery in real time, predicting blood sugar trends up to 30 minutes ahead.

An emerging category of technology sits at the intersection of monitoring and treatment. Smart microneedle patches are thin, wearable devices that use arrays of painless, hair-thin needles to both sense blood sugar through the skin and deliver insulin automatically when levels rise. Researchers have demonstrated these patches in animal studies, where they successfully maintained healthy blood sugar levels without any manual intervention.

A non-invasive glucose monitor, one that eliminates all skin puncture has been a long-standing goal in diabetes technology. While no such device has received FDA approval for clinical use yet, several have reached the stage of early human testing. Researchers are also developing smart contact lenses that measure glucose in tears, sweat-based biosensors built with flexible nanomaterials, and saliva-detecting sensors that could be integrated into dental devices.

Figure 2: Technological Realm for Diabetes

Regulatory and Clinical Guidance

The 2026 American Diabetes Association's Standards of Care now recommend continuous glucose monitoring from the time of diagnosis, include new treatment pathways incorporating the latest dual-hormone therapies, and emphasize behavioral health screening starting as early as age seven. In the UK, the updated National Institute for Health and Care Excellence guideline has made metformin plus an SGLT-2 inhibitor, the standard first-line therapy for nearly all adults with type 2 diabetes and requires active monitoring of equity in access to newer treatments.

The FDA is also adapting its regulatory framework to support innovation. In January 2026, the agency updated its guidance on digital health devices, clarifying that general wellness products like fitness trackers may follow a lighter regulatory path, while any device claiming to diagnose or manage diabetes still requires formal clearance.

Cell therapies demonstrate that insulin independence is achievable. New medications are reducing the burden of daily treatment. Non-invasive technologies are steadily closing the gap toward needle-free monitoring. AI is transforming raw data into personalized, predictive guidance. And regulatory frameworks are evolving to support rather than hinder these advances. The tools, therapies, and regulatory structures needed to fundamentally change the experience of living with diabetes are no longer theoretical. Many are already here. Others are very close. For the millions of people around the world who manage this condition every day, that represents something powerful: real, evidence-based reason for hope.

References

1. Afon Technology. Glucowear trial data. Presented at ATTD 2026, Barcelona.

2. American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl. 1). https://doi.org/10.2337/dc26-SREV 

3. He, Y., Chen, N., Zang, M., Zhang, J., Zhang, Y., Lu, H., Zhao, Q., Mao, Y., Yuan, Y., Wang, S., & Gao, Y. (2024). Glucose-responsive insulin microneedle patches for long-acting delivery and release visualization. Journal of controlled release : official journal of the Controlled Release Society, 368, 430–443. https://doi.org/10.1016/j.jconrel.2024.03.001

4. International Diabetes Federation. IDF Diabetes Atlas, 11th Edition. 2025. https://diabetesatlas.org

5. NICE. Type 2 diabetes in adults: management (NG28). Updated February 2026. https://www.nice.org.uk/guidance/ng28

6. Novo Nordisk. FDA approves Awiqli. Press release, March 26, 2026. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-awiqli-302726839.html

7. Vertex Pharmaceuticals. VX-880 clinical program. ClinicalTrials.gov: NCT04786262.

8. Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., & ATTAIN-1 Trial Investigators. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796–1806. https://doi.org/10.1056/NEJMoa2511774

9. Yazdani, J., Mafatia, K., Harun-Or-Rashid, M., Jabbour, J., Preda, V., & Nasiri, N. (2026). Tear-based glucose monitoring: A non-invasive approach to diabetes control in resource-limited settings. Biosensors & bioelectronics, 294, 118209. https://doi.org/10.1016/j.bios.2025.118209

10. Zhao, J., Xu, G., Yao, X., Zhou, H., Lyu, B., Pei, S., & Wen, P. (2022). Microneedle-based insulin transdermal delivery system: current status and translation challenges. Drug delivery and translational research, 12(10), 2403–2427. https://doi.org/10.1007/s13346-021-01077-3 

Assessed and Endorsed by the MedReport Medical Review Board